Navigation Links
Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
Date:7/10/2013

(PRWEB) July 10, 2013

On July 25 a judicial panel will consider the consolidation of federal Byetta, Januvia and Victoza lawsuits for pretrial purposes, according to court documents in In RE: Incretin Mimetics Products Liability Litigation (MDL-2452; U.S. Judicial Panel on Multidistrict Litigation). The Rottenstein Law Group LLP, a law firm that represents clients in Byetta, Victoza and Januvia lawsuits, explains the importance of this decision.

The three drugs each are designed to treat type-2 diabetes. The plaintiffs in the cases for the drugs all have common cause for suit, alleging that they suffered the same potentially dangerous side effects, according to court documents.

A March 2013 announcement* by the U.S. Food and Drug Administration mentioned findings similar to the allegations of the plaintiffs: That the drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas. Bristol-Myers Squibb subsidiary Amylin Pharmaceuticals makes Byetta, Merck Januvia and Novo Nordisk Victoza. Byetta and Januvia were also found to potentially increase the risk of thyroid cancer, according to the FDA, though the drugs’ labels did not notify patients of this alleged adverse side effect.**

“A multidistrict consolidation of the lawsuits involving the three drugs would benefit the plaintiffs because it could potentially improve efficiency in time-consuming, costly proceedings such as discovery,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “It reduces, or even eliminates, duplication of efforts.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged adverse side effects of Byetta, Januvia and Victoza to visit its FAQ page for quick answers to their questions about the drugs, their side effects and lawsuits. If there are additional questions, those looking for more information can use the contact form to get in touch with an attorney.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/januvia-lawsuits/pancreatic-cancer/prweb10913120.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuances of First Pretrial Order in Federal Stryker Hip Recall Litigation
2. ATA Hosts DC Summit on Federal Telemedicine and mHealth Policy
3. Bernstein Liebhard LLP Notes Plaintiffs’ Opposition to Defense Motion in Federal Litigation of DePuy Pinnacle Lawsuit Claims
4. Employers Are Choosing Orriant to Lower Overall Employee Healthcare Costs and Benefit from Federal Wellness Program Incentives
5. Mirena IUD Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Case Management Conference in Federal Mirena Side Effects Litigation
6. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
7. Federal Data Services Hub Does Exist, AISHealth.com Blog Post Reports
8. New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations
9. Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation
10. Federal Bar Association Chooses Marketing General Incorporated To Manage Mailing Lists
11. Biomet Hip Lawsuits Mount in Federal Biomet M2a Magnum Hip Replacement Litigation, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new ... the Bible about helping to stop cancer. Yisrayl says there are too many suffering and ... health and science industries will pay close attention and take action. The Pastor says that ...
(Date:5/6/2016)... ... ... “ Crossing Over: Affirmations of Faith in the Midst of the Dying ” ... vigil to glimpse into the supernatural as their lives ended. With her debut book, ... gain insight into providing care to terminal patients. , “I was inspired to ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... (LAIs), today announced a development collaboration with the Australian critical medicine company, ... disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits over ...
(Date:5/5/2016)... ... , ... TLC Laser Eye Centers announced today that it has acquired Gordon ... be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” , ... ensure that patients continue to receive the highest quality of care. In addition, all ...
(Date:5/5/2016)... ... 2016 , ... LELO has discovered many people are insecure about ... via email, social media and on the Volonté blog seeking advice about how to ... ‘normal’ or ‘correct’?” , While some methods are more common than others, there is ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 6, 2016 ... of liver disorders along with rise in obesity ... drugs in the coming few years. The NASH ... last five years on account of rising number ... is a large, un-tapped market with no FDA ...
(Date:5/5/2016)... -- , First quarter 2016 adjusted diluted ... million , First quarter reported diluted (GAAP) ... , Company revises 2016 financial guidance; now expects 2016 ... 2016 adjusted diluted non-GAAP earnings per share to range from ... regarding Generics business and manufacturing facility restructuring , ...
(Date:5/5/2016)... May 5, 2016 Research and Markets has ... in Top 5 EU Markets"  report to their offering.  ,     ... provides information on the current Positron Emission Tomography (PET) scanner ... (T5 EU), which includes France , ... Spain and the United Kingdom ...
Breaking Medicine Technology: